Waller E K, Barlett N, Chen C H, Mujic V, Sussman H, Toepker S, Grenier K
Stem Cell Biology Program, Emory University School of Medicine, Division of Hematology and Oncology, 1639 Pierce Drive, Room 2123, Atlanta, Georgia 30322, USA.
Cytotherapy. 1999;1(1):21-9.
The routine measurement of CD34+ cells in non-mobilized peripheral blood, using flow cytometry, has been limited by the technical difficulty of measuring the absolute numbers of rare populations of cells.
We studied the numbers of CD34+ cells in the peripheral blood of 55 normal volunteers and 476 cancer patients receiving chemotherapy, in a university out-patient hematology/oncology clinic. Blood samples were stained with MAbs to CD34, CD45 and a DNA-specific dye, mixed with a defined number of fluorescent True-Count beads and analyzed by flow cytometry, using an automated acquisition and analysis program.
The mean (+/- SD) CD34+ cell count among normal volunteers and previously untreated cancer patients were 1.4 +/- 1.4 and 1.8 +/- 2.8 CD34+ cells/microL, was stable among normal volunteers and patients receiving chemotherapy for prostate or breast cancer. In contrast, the CD34+ cell count among patients receiving dose-intensive weekly chemotherapy for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma varied between 1 cell/microL to > 300 CD34+ cells/microL in a predictable and cyclic fashion.
The study demonstrates that the routine measurement of the number of CD34+ cells in peripheral blood samples can be performed using an automated single platform program in an out-patient setting. The availability of an automated data acquisition and analysis program could facilitate standardization of counting CD34+ cells in clinical samples analyzed at different laboratory sites.
使用流式细胞术对未动员外周血中的CD34+细胞进行常规检测，一直受到测量稀有细胞群体绝对数量技术难度的限制。
在一所大学门诊血液学/肿瘤学诊所，我们研究了55名正常志愿者和476名接受化疗的癌症患者外周血中CD34+细胞的数量。血样用抗CD34、抗CD45单克隆抗体和一种DNA特异性染料染色，与一定数量的荧光真计数微球混合，并使用自动采集和分析程序通过流式细胞术进行分析。
正常志愿者和既往未治疗的癌症患者中CD34+细胞计数的平均值（±标准差）分别为1.4±1.4和1.8±2.8个CD34+细胞/微升，在正常志愿者以及接受前列腺癌或乳腺癌化疗的患者中保持稳定。相比之下，接受密集剂量每周化疗治疗霍奇金淋巴瘤或非霍奇金淋巴瘤的患者中，CD34+细胞计数以可预测的周期性方式在1个细胞/微升至>300个CD34+细胞/微升之间变化。
该研究表明，使用自动单平台程序可在门诊环境中对外周血样本中的CD34+细胞数量进行常规检测。自动数据采集和分析程序的可用性有助于在不同实验室地点分析的临床样本中对CD34+细胞计数进行标准化。
